Compare · HLF vs SCNX
HLF vs SCNX
Side-by-side comparison of Herbalife Ltd. (HLF) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HLF and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- HLF is the larger of the two at $1.18B, about 81.0x SCNX ($14.6M).
- Over the past year, HLF is up 44.9% and SCNX is down 65.5% - HLF leads by 110.5 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- HLF has more recent analyst coverage (14 ratings vs 0 for SCNX).
- Company
- Herbalife Ltd.
- Scienture Holdings Inc.
- Price
- $11.50+0.66%
- $0.36+0.36%
- Market cap
- $1.18B
- $14.6M
- 1M return
- -20.58%
- -14.20%
- 1Y return
- +44.93%
- -65.54%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 5
- 5
- Recent ratings
- 14
- 0
Herbalife Ltd.
Herbalife Nutrition Ltd. offers nutrition solutions in North America, Mexico, South and Central America, Europe, the Middle East, Africa, and the Asia Pacific. The company provides products in the areas of weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition. It offers weight management products, including meal replacement products, protein shakes, drink mixes, weight loss enhancers, and healthy snacks; targeted nutrition products, which include functional beverages, and dietary and nutritional supplements that contain herbs, vitamins, minerals, and other natural ingredients; outer nutrition products, such as facial skin, body, and hair care products; and energy, sports, and fitness products comprising N-R-G tea and energy drink products. The company also provides literature, promotional, and other materials that include start-up kits, sales tools, and educational materials. It offers its products through independent service providers and sales representatives, as well as through company-operated retail platforms. The company was formerly known as Herbalife Ltd. and changed its name to Herbalife Nutrition Ltd. in April 2018. Herbalife Nutrition Ltd. was founded in 1980 and is headquartered in Los Angeles, California.
Latest HLF
- Director L'Helias Sophie bought $13,572 worth of shares (1,200 units at $11.31), increasing direct ownership by 2% to 79,882 units (SEC Form 4)
- Herbalife Named to Three 2026 USA TODAY Most Trusted Brands Lists
- Herbalife Chief Financial Officer to Present at East Coast IDEAS Conference on June 11
- Amendment: New insider Walsh Des claimed ownership of 50,000 shares (SEC Form 3)
- Chief Operating Officer Hicks Troy sold $619,556 worth of shares (48,377 units at $12.81), exercised 83,270 shares at a strike of $9.31 and covered exercise/tax liability with 72,626 shares, decreasing direct ownership by 80% to 9,706 units (SEC Form 4)
- Roman DBDR Acquisition Corp. II Appoints Hunter Gary to Board of Directors and Al Basseri as Chief Technology Officer, Ahead of Proposed Business Combination with ThomasLloyd Climate Solutions
- Chief Commercial Officer Lamberti Frank sold $1,932,259 worth of shares (142,919 units at $13.52), decreasing direct ownership by 80% to 36,624 units (SEC Form 4)
- Director Cloud Lynda was granted 11,879 shares, increasing direct ownership by 31% to 50,736 units (SEC Form 4)
- Director Otero Maria was granted 11,879 shares, increasing direct ownership by 14% to 95,129 units (SEC Form 4)
- Director Carmona Richard H was granted 11,879 shares, increasing direct ownership by 17% to 83,645 units (SEC Form 4)
Latest SCNX
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline
- SCIENTURE Announces Third Patent Grant for ARBLI™ (losartan potassium) Oral Suspension, Strengthening Long-Term Market Exclusivity Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Scienture Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits